Allopurinol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Allopurinol: From Gout / Hyperuricemia to Hepatic Porphyria
One-Sentence Summary
Allopurinol is a well-established xanthine oxidase (XO) inhibitor, primarily used to treat gout and hyperuricemia by reducing uric acid synthesis. The TxGNN model predicts it may be effective for Hepatic Porphyria, with 0 clinical trials and 2 publications currently supporting this direction. The mechanistic rationale is biologically plausible but remains at the hypothesis stage, placing this candidate at evidence level L4.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gout / Hyperuricemia (not retrievable from NZ regulatory data; 0 registered licenses) |
| Predicted New Indication | Hepatic Porphyria |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Allopurinol is a xanthine oxidase (XO) inhibitor that blocks the conversion of hypoxanthine → xanthine → uric acid, explaining its efficacy in gout and hyperuricemia. Beyond XO inhibition, allopurinol has also been reported to suppress the activity of δ-aminolevulinate synthase (ALAS) — the rate-limiting enzyme of hepatic heme biosynthesis.
Hepatic porphyria (including acute intermittent porphyria and related disorders) is mechanistically defined by excessive ALAS overactivation, leading to toxic accumulation of precursors such as δ-aminolevulinic acid (ALA) and porphobilinogen (PBG). If allopurinol's ALAS-suppressive activity operates in hepatic tissue, it could in principle reduce this toxic precursor burden — providing a direct molecular link between the drug's secondary pharmacology and the disease's core pathophysiology.
PMID 31443750 (Badawy, 2019, Medical Hypotheses) directly proposes metabolic targeting of hepatic ALAS as a strategy for acute hepatic porphyrias, discussing heme feedback regulation and relevant enzymatic pathways. This hypothesis paper gives the TxGNN prediction a biologically coherent anchor. However, there is no clinical trial data and no controlled human evidence to date; this remains a preclinical/mechanistic-level candidate (L4).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31443750 | 2019 | Hypothesis / Mechanistic Review | Medical Hypotheses | Proposes metabolic targeting of hepatic ALAS via TDO inhibition or tryptophan as therapy for acute hepatic porphyrias; discusses heme biosynthesis feedback loops and enzymatic pathways directly relevant to allopurinol's potential mechanism of action in porphyria |
| 1567472 | 1992 | Animal Study (Rat, in vivo) | Biochemical Pharmacology | Examines carbamazepine's acute effects on haem metabolism in rat liver via a porphyria exacerbation screening model; characterises drug interactions with heme/tryptophan pyrrolase pathway, providing mechanistic context for heme pathway drug effects |
New Zealand Market Information
Allopurinol currently has no registered authorizations in the New Zealand regulatory database. No licensed products, dosage forms, or approved indications are on record. This is notable given allopurinol's widespread global use — independent verification against Medsafe's online database is recommended before drawing regulatory conclusions.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction carries a plausible molecular basis — allopurinol's reported ALAS-inhibitory effect aligns directly with the core pathophysiology of hepatic porphyria — but is supported only by a single hypothesis paper and an indirect animal study, with no clinical trial evidence whatsoever. The L4 evidence level does not support clinical development without dedicated preclinical validation.
To proceed, the following is needed:
- Dedicated preclinical studies in established hepatic porphyria animal models (e.g., AIP mouse model) measuring the effect of allopurinol on urinary ALA/PBG excretion and ALAS activity
- Confirmation and quantification of allopurinol's ALAS-inhibitory potency in hepatic tissue (separate from its XO-inhibitory primary mechanism)
- Full mechanism of action documentation via DrugBank API query (currently a High-severity data gap)
- Safety profile review via Medsafe/TFDA package insert — currently a Blocking data gap that prevents formal safety screening
- Independent verification of NZ market status against the Medsafe database, given the discrepancy with global availability of this drug
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.